The clinical use of a preparation based on phyto-oestrogens in the treatment of menopausal disorders. Act Biomed Ateneo Parmense. 2003 Dec; 74(3):137-43
Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr. 1998 Dec; 68(6 Suppl):1375S-1379S
Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 1999 Oct; 84(10):3647
Alternative treatments for menopause symptoms: Systematic review of scientific and lay literature. Can Fam Physician. 1998 Jun; 44:1299-308
Effects of Phytoestrogens on Bone Turnover in Postmenopausal Women with a History of Breast Cancer: The Journal of Clinical Endocrinology and Metabolism Vol. 89, No. 3 1207-1212
Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiology 1997; 145(6):536-45.
Writing Group for the Women's Health Initiative; Risks and benefits of combined estrogen and progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA-EXPRESS 2002
Tavani A, La Vecchia C. The adverse effects of hormone replacement therapy. Drugs Aging 1999; 14(5):347-57.
Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89:1110-1116
Beresford S, Weiss N, Voigt L, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458-461
Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 2002; 288:49-57.
Rosano GM, Painina G. Cardiovascular pharmacology of hormone replacement therapy. Drugs Aging 1999; 15(3):219-234
Reid IR. Pharmacological management of osteoporosis in postmenopausal women: a comparative review. Drugs Aging 1999; 15(5):349-63.
Rosenberg S. Vandromme J, Ayata NB, et al. Osteoporosis Management. Int J Fertile Womens Med 1999; 44(5):241-9.
Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy. Lancet 1997; 350:1047-1059
Ross RK, Paganini-Hill A, Wan PC, et al. Effective hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl. Cancer Inst 2000; 92:328-332
Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283(4):485-491.
Schairer C, Gail M, Byrne C, Rosenberg P, Sturgeon S, Brinton L, Hoover R. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst, 1999; 91:264-70.
Lacey JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer in a prospective study. JAMA 2002.
Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen: Replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285:14
Weiss NS, Rossing MA. Oestrogen-replacement therapy and risk of ovarian cancer: Lancet 2001; 358:438.
Riman T, Dickman PW, Nilsson S, Correria N, Nordlinder H, Magnusson CM, Weiderpass E, Persson I. Hormone replacement therapy and the risk of invasive ovarian cancer in Swedish women. J Natl: Cancer Inst 2002; 94:497-504.
Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA, Heary and Estrogen/Progestin Replacement Study Research Group: Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study trial. JAMA 2002; 287:591-596.
International Position Paper on Women's Health and Menopause: A Comprehensive Approach. Best Clinical Practices: 2002; Chapter 13.
Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninhake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study: Ann Intern Med 2000; 132:689-696.
Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 2002; 288:58-66.
Simon JA, Hunninghake DB, Agarwal SK, Cauley JA, Ireland CC, Pickar JH: Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease; The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2001; 135:493-501.
Kakar F, Weiss NS, Strite SA. Non contraceptive estrogen: Use and risk of gallstone disease in women. Am. J Public Health 1988; 78:564.
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280(7):605-613.
Castellsague J, Perez Gutthann S, Garcia Rodriguez LA: Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review Drug Safety 1998; 18(2):117-23.
Seifert M, Galid A, Kubista E. Estrogen replacement therapy in women with a history of breast cancer. Maturitas 1999; 32(2):63-8.
Burger CW, van Leeuwen FE, Scheele F, Kenemans P. Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 1999; 32(2):69-76.
O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, and Weiss NS: Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl, Cancer Inst 2001; 93:754-62.
Baker VL: Alternatives to oral estrogen replacement. Obstet Gynecol Clin North Am 1994; 21(2):271-97.
Sturdee DW. Current hormone replacement therapy: what are the shortcomings? Advances in delivery. Int J Clin. Pract: 1999; 53(6):468-472.
Ansbacher R. The pharmokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol: 2001; 184: 255 – 263
Mosca, L, Grundy SM, Judelson D, King K, Limacher M, Oparil S, Pasternak R, Pearson TA, Redberg RF, Smith SC, Winston M, Zinberg S. Guide to preventive cardiology for women. Circulation 1999: 99:2480-2484.
Seed M, Sands RH, McLaren M, Kirk G, Darko D. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women. Fam. Pract 2000; 17:497-507.
Keller C, Fullerton J, Mobley C. Supplemental and complementary alternatives to hormone replacement therapy. Amer Acac Nurse Pract 1999; 11(5):187-98.
Raloxifene approval ushers in new drug class for osteoporosis. Estrogen-receptor effects vary by tissue type. Am J Health Syst Pharm 1998; 55(2):104.
The Women's Health Initiative Study Group: Design of the Women's Health Initiative clinical trial and observational study: Control Clin Trials 1998; 19(1):61-109.
Brekwoldt M, Keck C, Karck U. Benefits and risks of hormone replacement therapy (HRT). J Steroid Biochem Mol Bio 1995; 53(1-6):205-8.
Brinton LA, Schairer C. Postmenopausal hormone-replacement therapy: time for reappraisal? N Engl J Med 1997; 336(25):1821-1822.
Bush TL, Whiteman MK. Hormone replacement therapy and risk of breast cancer. Editorial JAMA 1999; 281(22):2140-2141.
Oates MB, McGhan WF, Smith MD. Hormone replacement therapy: a review of the risk versus benefit-Part II. Med Interface 1997; 10(1):108-14.
Colditz G, Rosner B, for the Nurses' Health Study Research Group. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol 1998; 147(suppl):84S.
Persson I, Weiderpass E, Bergvist L, et al. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement: Cancer Causes Control 1999; 10(4):253-260.